Chemotherapy for Participants With Lymphoma

An Open-label, Single Arm, Phase 2 Study of Rituximab, Gemcitabine and Oxaliplatin Plus Enzastaurin as Treatment for Patients With Relapsed Diffuse Large B-Cell Lymphoma

The primary purpose of this study is to help answer the following research questions:

• To assess whether Enzastaurin combined with rituximab, gemcitabine and oxaliplatin (R-GEMOX) can help participants with Diffuse Large B-Cell Lymphoma (DLBCL) remain free from disease and thus live longer.
• To assess for any side effects that might be associated with enzastaurin and R-GEMOX .
• To look at the characteristics and levels of certain genes and proteins to learn more about DLBCL and how enzastaurin works in the body.
• To look at the level of enzastaurin in the body and how long it remains.

Inclusion Criteria:

• Diagnosis of DLBCL or transformed (cluster differentiation 20 [CD20]+) indolent lymphoma
• Relapsed/progressed after response obtained in 1st- or 2nd-line treatment, or participants who have not progressed after stable disease (SD) obtained in 1st- or 2nd-line.
• Measurable disease (lymph node greater than 1.5 cm)
• Adequate organ function
• Greater than or equal to 60 years or less than 60 (but greater than or equal to 18 years) who are not eligible for high-dose chemotherapy high-dose chemotherapy (HDC) and autologous stem cell transplant (ASCT)

Exclusion Criteria:

• Prior Allogeneic transplantation
• More than 2 prior anticancer treatment regimens
• Pregnant or breastfeeding
• Human-immunodeficiency-virus (HIV)associated lymphomas
• Brain metastases